Skip to main content
Jeffrey Lancet, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

JeffreyELancetMD

Oncology • Tampa, FL

Hematologic Oncology

Senior Member, Department Chair - Malignant Hematology Professor of Oncologic Sciences, University of South Florida

Request Appointment

Overview of Dr. Lancet

Dr. Jeffrey Lancet is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from SUNY Upstate Medical University and has been in practice 25 years. Dr. Lancet accepts several types of health insurance, listed below. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of Rochester
    University of RochesterFellowship, Hematology and Medical Oncology, 1996 - 1999
  • Rochester Regional Health/Unity Hospital (Rochester)
    Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1995 - 1996
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1992 - 1995
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityClass of 1992

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2004 - 2025
  • NY State Medical License
    NY State Medical License 1994 - 2006
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...  
    Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
  • A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
    Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

  • Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
    Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
    Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
    Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • AML: Expert Guidance on Current Standards and New Directions in Patient Care 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
  • State of the Art Update and Next Questions: Acute Myeloid LeukemiaOctober 2017

Press Mentions

  • COVID-19 Takes a Toll on People with Blood Cancers and Disorders
    COVID-19 Takes a Toll on People with Blood Cancers and DisordersDecember 11th, 2021
  • New AML Approvals Changing the Treatment Landscape
    New AML Approvals Changing the Treatment LandscapeSeptember 8th, 2017
  • Emerging Agents Poised to Transform AML Landscape
    Emerging Agents Poised to Transform AML LandscapeJuly 17th, 2017
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access PPO
    Anthem Blue Preferred HMO
    Anthem Blue Preferred Plus POS
    Anthem KeyCare PPO
    AvMed Health Open Access
    BCBS Blue Card PPO
    BCBS Florida BlueCare HMO
    BCBS Florida NetworkBlue
    BCBS Florida Preferred Patient Care PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Coventry Carelink Health Plans PPO
    Coventry Florida - Employer Group PPO
    Coventry Virginia - HMO
    First Health PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Network Health Plan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
    WEA Trust POS-SE
    WEA Trust Preferred Provider Plan - Trust Pref
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Jeffrey Lancet, Dr. Jeffrey Lancet, MD, Dr. J Lancet, Dr. Jeffrey E Lancet